Payment overview · 2025
General Payments
$14.56
1 reported records · 1 companies
Healthcare provider profile · identity verified
Dorene M Morris, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TUSCUMBIA, AL · NPI 1760455539
Verified facts
What the public records show
CMS Open Payments records show Dorene M Morris, D.O. received $14.56 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.56 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1057 | 124 |
| Gabapentin | Gabapentin | 710 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 592 | 145 |
| Oxycodone Hcl | Oxycodone Hcl | 524 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 502 | 59 |
| Alprazolam | Alprazolam | 470 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 91 |
| Promethazine Hcl | Promethazine Hcl | 311 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 295 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 81 |
| Clonazepam | Clonazepam | 272 | 32 |
| Montelukast Sodium | Montelukast Sodium | 243 | 56 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 224 | 50 |
| Tramadol Hcl | Tramadol Hcl | 223 | 39 |
| Mirtazapine | Mirtazapine | 213 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 212 | 30 |
| Pregabalin | Pregabalin | 209 | 37 |
| Lisinopril | Lisinopril | 200 | 60 |
| Sertraline Hcl | Sertraline Hcl | 193 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 48 |
| Omeprazole | Omeprazole | 183 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 44 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 170 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 165 | 48 |
| Buspirone Hcl | Buspirone Hcl | 161 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 41 |
| Trazodone Hcl | Trazodone Hcl | 134 | 24 |
| Furosemide | Furosemide | 128 | 36 |
| Potassium Chloride | Potassium Chloride | 126 | 36 |
| Losartan Potassium | Losartan Potassium | 123 | 34 |
| Sucralfate | Sucralfate | 121 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 26 |
| Methocarbamol | Methocarbamol | 109 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 109 | 28 |
| Allopurinol | Allopurinol | 99 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 28 |
| Meloxicam | Meloxicam | 97 | 20 |
| Amoxicillin | Amoxicillin | 96 | 65 |
| Mupirocin | Mupirocin | 96 | 50 |
| Alendronate Sodium | Alendronate Sodium | 95 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 26 |
| Ozempic | Semaglutide | 94 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 22 |
| Mounjaro | Tirzepatide | 89 | 14 |
| Clonidine Hcl | Clonidine Hcl | 85 | 25 |
| Eliquis | Apixaban | 85 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 17 |
| Nystatin | Nystatin | 83 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 20 |
| Lorazepam | Lorazepam | 79 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 11 |
| Lidocaine | Lidocaine | 73 | 25 |
| Simvastatin | Simvastatin | 72 | 17 |
| Ezetimibe | Ezetimibe | 70 | 21 |
| Cefdinir | Cefdinir | 67 | 47 |
| Prednisone | Prednisone | 66 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 18 |
| Linzess | Linaclotide | 64 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 47 |
| Ondansetron Odt | Ondansetron | 61 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 11 |
| Carvedilol | Carvedilol | 58 | 14 |
| Diazepam | Diazepam | 58 | 12 |
| Fluconazole | Fluconazole | 57 | 23 |
| Famotidine | Famotidine | 56 | 11 |
| Metformin Hcl | Metformin Hcl | 56 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Estradiol | Estradiol | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 23 |
| Clonidine | Clonidine | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 25 |
| Fentanyl | Fentanyl | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 13 |
| Temazepam | Temazepam | 33 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Valproate Sodium | Valproic Acid (As Sodium Salt) | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 28 | suppressed |
| Indomethacin | Indomethacin | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 11 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Ztlido | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.56 · 1 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error